In addition, the study highlights Cisd2 as a novel drug target for the development of therapies to delay cardiac dysfunction (Yeh et al., 2019); The relationship between inflammation and the onset of HF has long been recognized, but current therapies aimed at reducing inflammation in patients with HF have not shown appreciable results (Adamo et al., 2020). The gene discussed is CISD2; the disease is hydrops fetalis.